Amarin Corp Plcuk (AMRN) Enterprise Value (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Enterprise Value of -$177.0 million for Q1 2026, down 8.88% year-over-year from -$194.3 million in Q1 2025, and up 41.5% quarter-over-quarter from -$302.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Enterprise Value (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Enterprise Value data on file, last reported at -$177.0 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$177.0 million, down 8.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$177.0 million (down 8.88% YoY), and the FY2025 annual result was -$302.6 million, down 74.42% from the prior year.
- Enterprise Value improved to -$177.0 million in Q1 2026 per AMRN's latest filing, from -$302.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$50.4 million in Q3 2023 and troughed at -$362.6 million in Q1 2022.
- A 5-year average of -$198.7 million and a median of -$173.5 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value surged 85.99% in 2022, then plunged 506.86% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$92.2 million in 2022, then slumped by 32.22% to -$121.9 million in 2023, then tumbled by 42.28% to -$173.5 million in 2024, then plunged by 74.42% to -$302.6 million in 2025, then jumped by 41.5% to -$177.0 million in 2026.
- Business Quant data shows AMRN's Enterprise Value at -$177.0 million in Q1 2026, -$302.6 million in Q4 2025, and -$164.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -177.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.00 Mn |
| Dec 31, 2025 | -302.59 Mn |
| Sep 30, 2025 | -164.10 Mn |
| Jun 30, 2025 | -298.70 Mn |
| Mar 31, 2025 | -162.56 Mn |
| Dec 31, 2024 | -173.48 Mn |
| Sep 30, 2024 | -305.69 Mn |
| Jun 30, 2024 | -306.60 Mn |
| Mar 31, 2024 | -94.76 Mn |
| Dec 31, 2023 | -121.93 Mn |
| Sep 30, 2023 | -50.37 Mn |
| Jun 30, 2023 | -80.42 Mn |
| Mar 31, 2023 | -304.37 Mn |
| Dec 31, 2022 | -92.22 Mn |
| Sep 30, 2022 | -67.12 Mn |
| Jun 30, 2022 | -313.23 Mn |
| Mar 31, 2022 | -362.61 Mn |
| Dec 31, 2021 | -454.13 Mn |
| Sep 30, 2021 | -479.20 Mn |
| Jun 30, 2021 | -185.83 Mn |